Physician profile
Chase Helm
NPI 1821589870
$4,218.45
in general payments reported to CMS, 2019-2025
31 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $924 · 2023: $1,093 · 2024: $1,251 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $646.01 | 2022-2025 | |
| Lilly USA, LLC | $546.97 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $333.02 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $306.14 | 2022-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $301.94 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $239.80 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $218.05 | 2022-2025 | Veozah |
| Exact Sciences Corporation | $216.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $205.45 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Amgen INC. | $117.86 | 2021-2024 | Prolia, Evenity, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.83 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $110.99 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.40 | 2021-2023 | Synjardy, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $103.34 | 2022-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $83.52 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $77.89 | 2022-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $74.22 | 2023-2025 | Auvelity |
| Amarin Pharma, INC. | $64.38 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.64 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.43 | 2022-2025 | Xifaxan |
| Abbott Laboratories | $42.78 | 2025 | Freestyle Libre 3, Assurity |
| Janssen Pharmaceuticals, INC | $31.51 | 2022 | |
| Medtronic, INC. | $30.16 | 2021-2024 | Minimed 780g |
| Nestle Healthcare Nutrition INC. | $23.48 | 2022 | |
| Genentech USA, INC. | $20.89 | 2022 | |
| Biogen, INC. | $18.43 | 2024 | Skyclarys |
| Arbor Pharmaceuticals, INC. | $15.43 | 2021 | |
| Sanofi Pasteur INC. | $14.53 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.52 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $12.89 | 2023 | Rexulti |
| Agios Pharmaceuticals, INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.